Catalyst
Slingshot members are tracking this event:
Sage Therapeutics (SAGE) Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SAGE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 19, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Sage-217, Mood Disorders, Phase 2
